Juno Therapeutics, Inc., A Bristol-myers Squibb Company

This study tests a new treatment called arlocabtagene autoleucel (BMS-986393) for adults with multiple myeloma that has come back or not responded to other therapies. The treatment uses a patient's own immune cells, modified to target and kill cancer cells. The goal is to see if …

This early-stage study tests a cell therapy (arlocabtagene autoleucel) combined with other drugs in about 147 people whose multiple myeloma has come back or stopped responding to prior treatments. The main goals are to find safe doses and check for side effects, while also seeing…

This early-phase study tests a new treatment called BMS-986515 for people with severe autoimmune diseases that haven't responded to standard therapies. The treatment uses immune cells from a healthy donor, modified to target and potentially calm the overactive immune system. The …

This early-stage study tests a new treatment called CC-97540, which uses a patient's own immune cells engineered to target and destroy faulty immune cells causing disease. It is for people with severe forms of lupus, myositis, scleroderma, or rheumatoid arthritis that have not re…

This early-stage trial tests a new treatment called CC-97540, which uses specially engineered immune cells (CAR T cells) to target and calm the immune system in people with multiple sclerosis or myasthenia gravis. The study aims to see if the therapy is safe and tolerable, and to…

This study tests a new treatment called arlocabtagene autoleucel (arlo-cel), a CAR-T cell therapy that targets a protein called GPRC5D on myeloma cells. It is for adults with multiple myeloma that has come back or not responded to treatment, and who have already used lenalidomide…